LALINDEN ADVISORS LP

Institutional investor · Portfolio as of Q2 2026

Top Holdings638 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
418.1M$829.5M4.3%
Increased
88
??MKS INC.
Bond
201.3M$593.3M3.1%
Increased
58
533.8M$590.9M3.1%
New
87
204.3M$514.2M2.7%
Increased
81
224M$444.5M2.3%
Decreased
0
99.5M$395.7M2.1%
Decreased
0
225.8M$367.4M1.9%
Increased
57
71.5M$350.6M1.8%
Decreased
0
118.2M$315.3M1.6%
Increased
64
155.4M$299.3M1.6%
Increased
69
97.9M$277.4M1.4%
Increased
78
241.4M$273.4M1.4%
Decreased
0
239.7M$266.3M1.4%
Increased
48
132.1M$266M1.4%
Increased
52
197.8M$258.2M1.3%
Increased
50
112.9M$254.5M1.3%
Increased
58
281.8M$250.9M1.3%
New
70
44M$247.3M1.3%
Unchanged
0
210.9M$246.2M1.3%
Decreased
0
254.2M$245.8M1.3%
Increased
48
$19.3B
AUM
638
Positions
Q2 2026
Filing
2.0/5
HI score
Quarterly 13F Value Change
+22%Q1'25$14.7B+10%Q2'25$16.3B-8%Q3'25$15B+8%Q4'25$16.2B+10%Q1'26$17.9B+8%Q2'26$19.3B
Activity profile
$ moved · Q2'26
New30%Increased23%Decreased27%Exited19%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.7 quarters
<1Q25%1-4Q47%1-2Y21%2Y+7%

LINDEN ADVISORS LP manages $19.3B across 638 positions as of Q2 2026. Top holdings: VISHAY INTERTECHNOLOGY INC (4.3%), MKS INC. (3.1%), SITIME CORP (3.1%). Fund DNA: Momentum Trader. HoldingsIntel Score: 2/5.0.

Q2 2026 Summary

Active quarter - 168 new positions, 93 exits, 66 increased. No standout high-conviction moves this quarter. Portfolio: $19.3B across 638 positions.

Top holdings by portfolio weight

Total AUM$19B
VISHAY INTER4.30%
MKS INC.3.07%
SITIME CORP3.06%
GUARDANT HEA2.66%
CENTRUS ENER2.30%
APPLIED DIGI2.05%
SOLARIS ENER1.90%
SPHERE ENTER1.82%
VEECO INSTRU1.63%
SOLAREDGE TE1.55%
Other1.44%

Portfolio allocation by GICS sector

Sectors9
Financial Services63.70%
Communication Services18.12%
Unknown16.47%
Healthcare0.70%
Real Estate0.41%
Industrials0.21%
Energy0.17%
Technology0.14%
Utilities0.06%

Behavioral investing profile

Checking access…
Momentum Trader
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(2.0 / 5.0)
Holdings P&L62
Conviction31
Concentration37
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
8Q
BR10806XAD4BRIDGEBIO PHARMA INC
Q3 2024 Q2 2026+157.4M shares+$200.5M
7Q
VI928298AR9VISHAY INTERTECHNOLOGY INC
Q4 2024 Q2 2026+353.9M shares+$770.5M
4Q
CO19459JAC8COLLEGIUM PHARMACEUTICAL INC
Q3 2025 Q2 2026+26.6M shares+$50.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used